Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026 The trial has already yielded encouraging one- and two-year data including a 75% Objective Response Rate COPENHAGEN, Denmark, April 7, 2026 - Evaxion A/S (NASDAQ: EVAX)